{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 49,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "roadmap",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a matrix-like layout to map drug candidates against biological targets and development status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/11",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.91,
        "x": 0.045,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Pipeline matrix showing C5, Oral Factor D, Factor P, C3 siRNA, and Factor H targets across development stages.",
      "attrs": null,
      "subkind": "matrix-nxn",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e6c596b-e904-4939-b3c8-f9957c446dce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome; gMG = generalised myasthenia gravis; NMOSD = neuromyelitis optica spectrum disorder; GBS = Guillain-Barré syndrome; DM = dermatomyositis; HSCT-TMA = haematopoietic stem cell transplant-associated thrombotic microangiopathy; CM-TMA = complement-mediated thrombotic microangiopathy; CSA-AKI = cardiac surgery-associated acute kidney injury; PNH-EVH = paroxysmal nocturnal haemoglobinuria with extravascular haemolysis; GA = geographic atrophy; SCD = sickle cell disease; siRNA = small interfering RNA; cAMR = chronic antibody-mediated rejection.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d9cf995-eb44-48ab-8527-b939b590b73a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.93,
        "x": 0.035,
        "y": 0.14
      },
      "kind": "title",
      "text": "Multiple development-stage platforms, leveraging foundational complement expertise",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e584e76-9b32-47d2-91b1-209d8fbb067e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.035,
        "y": 0.07
      },
      "kind": "title",
      "text": "Broad expertise in complement biology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74325178-6307-47ea-84b3-74107f41b7a0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "a801e760-7cab-4238-8fe0-83dffebfd02d",
      "evidence": "Pipeline matrix showing C5, Oral Factor D, Factor P, C3 siRNA, and Factor H targets across development stages.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "cb07ef9a-8f83-4715-8fec-6989ed26b90a",
      "evidence": "The slide organizes drug assets into a grid based on biological targets (columns) and development stages (rows/shading).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 19,
      "from": 10,
      "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 10,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b",
      "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs",
      "position": 1,
      "objective": "How AstraZeneca's pipeline addresses high unmet medical needs",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.6,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}